#1leading
VEGF is the central driver of multisystem disease manifestations in POEMS syndrome
35 studies·pathogenesis
85
evidence
POEMS Syndrome
Also known asPOEMSCrow-Fukase SyndromeTakatsuki Syndrome
POEMS syndrome is a rare paraneoplastic disorder caused by an underlying clonal plasma cell neoplasm. The acronym POEMS stands for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes — though the syndrome encompasses far more features including sclerotic bone lesions, Castleman disease, papilledema, extravascular volume overload, and thrombocytosis.
Data sourced from 33 published studies with evidence grading (A–D). Last reviewed . Not medical advice.
Pathophysiology◐Partially understood
Treatment✓Effective options available
Genetic basis○Under investigation
Research activity
33 studies·0 active trials·1980–2023
Epidemiology
- Total cases
- Unknown
- Mean onset
- 52 years
- Onset range
- 21–84 years
- Sex ratio (M:F)
- 1.5:1
- Diagnostic delay
- ~1.5 years
- Discovered
- 1956 (R.S. Crow (first description); P.A. Bardwick (coined POEMS acronym, 1980))
- Prevalence
- ~0.3/100,000
- Classification
- Hematologic, Paraneoplastic
Cardinal Features
11 key symptoms and signs
| Feature | Frequency | Category | Sources |
|---|---|---|---|
Polyneuropathy Progressive ascending symmetric sensorimotor demyelinating polyneuropathy. Starts with distal numbness and tingling in feet, progressing to motor weakness. Uniform demyelination (intermediate segments) with severe axonal loss in lower limbs. Distinguished from CIDP by less conduction block, less temporal dispersion, and absent sural sparing. | 100% | neurologic | |
Monoclonal plasma cell disorder (lambda-restricted) Clonal plasma cell proliferative disorder with >95% lambda light chain restriction. Characteristically uses IGLV1-44 or IGLV1-40 germline gene segments. Bone marrow plasma cell percentage is typically low (<5% in most cases), unlike multiple myeloma. | 100% | laboratory | |
Elevated VEGF Serum VEGF levels typically 5-10 fold above normal (median ~4000 pg/mL). Serum VEGF >1000 pg/mL with demyelinating neuropathy and lambda monoclonal protein has 100% sensitivity and 93% specificity for POEMS. Plasma VEGF avoids platelet-derived confounding. Levels correlate with disease activity and decline with treatment. | 96% | laboratory | |
Sclerotic bone lesions Osteosclerotic (not lytic) bone lesions are characteristic. Present in ~95% of patients. Can be solitary or multiple. Distinguished from myeloma by sclerotic rather than lytic pattern. CT is more sensitive than plain radiographs. PET-CT may show FDG avidity. | 95% | skeletal | |
Skin changes Present in ~90% of patients. Hyperpigmentation and hemangioma most common (47%). Other features include hypertrichosis (38%), acrocyanosis (34%), Raynaud phenomenon (20%), sclerodermoid changes (26%), white nails (30%), and clubbing (6%). Glomeruloid hemangioma (~3%) is pathognomonic for POEMS. | 90% | dermatologic | |
Endocrinopathy 84% have recognized endocrinopathy at diagnosis; 92% develop one during follow-up. Hypogonadism most common (79% of men). Hypothyroidism (20-36%), hyperprolactinemia (56-63%), abnormal glucose metabolism (48%), and adrenal insufficiency (14%) also prevalent. Mechanisms poorly understood. Baseline hypothyroidism predicts worse PFS and OS. | 84% | endocrine | |
Extravascular volume overload Peripheral edema, ascites, pleural effusion, and pericardial effusion. Present in ~80% of patients. Driven by VEGF-mediated increased vascular permeability. Pleural effusion is an independent risk factor for poor OS. Resolves with successful treatment of the plasma cell clone. | 80% | systemic | |
Organomegaly Hepatomegaly, splenomegaly, and/or lymphadenopathy present in approximately 50% of patients. Lymphadenopathy may show Castleman disease-like histology. Spleen and liver enlargement likely VEGF-driven. | 50% | systemic | |
Papilledema Bilateral papilledema present in 29-64% of patients. Usually asymptomatic but may cause headaches, brief visual obscurations, scotomata, and visual field constriction. Not associated with raised intracranial pressure. Cause unknown but likely VEGF-mediated. Associated with unfavorable prognosis. | 52% | ophthalmic | |
Pulmonary hypertension Present in 33-48% of patients. Associated with dyspnea (50% of PH patients vs 19% without). Patients with PH have worse median survival (54 months vs not reached). Responds to treatment of the underlying plasma cell clone. May be steroid-responsive. | 40% | cardiopulmonary | |
Castleman disease (co-occurring) Present in 11-30% of POEMS patients. Typically multicentric Castleman disease with plasma cell variant histology. Shares IL-6 and VEGF elevation. The Castleman disease variant of POEMS has no clonal plasma cell disorder and typically less peripheral neuropathy. Histologically shows atrophied germinal centers with concentrically arranged mantle zones. | 20% | hematologic |
Hypothesis Tracker
Competing explanations ranked by evidence weight
#2leading
VEGF-induced vascular permeability is the primary mechanism of organomegaly, edema, and effusions
20 studies·organ_damage
75
evidence
#3emerging
Clonal plasma cells drive disease via a cytokine cascade initiated by IL-6, not direct VEGF production
12 studies·pathogenesis
65
evidence
#4competing
Sclerotic bone lesions result from cytokine-mediated osteoblast activation rather than direct tumor infiltration
8 studies·bone_pathology
55
evidence
Open Questions
Why is POEMS syndrome almost exclusively lambda light chain restricted?
Over 95% of POEMS patients have lambda-restricted monoclonal protein, with stereotypic IGLV1-44 or IGLV1-40 gene usage. This extreme restriction suggests antigen-driven clonal selection, but the triggering antigen remains unknown.
Why are bone lesions sclerotic rather than lytic in POEMS, unlike other plasma cell dyscrasias?
Multiple myeloma causes lytic bone destruction, yet POEMS — also driven by clonal plasma cells — produces osteosclerotic lesions. The mechanism of this divergence is poorly understood but may relate to the cytokine milieu (high VEGF, IL-6) preferentially stimulating osteoblasts.
Why is thrombocytosis/polycythemia a feature of POEMS rather than the cytopenias seen in myeloma?
POEMS patients frequently have elevated platelet counts and sometimes polycythemia, the opposite of the cytopenias typical of myeloma. This may relate to thrombopoietin or erythropoietin stimulation by VEGF or other cytokines, but the mechanism is unproven.
By what mechanism does VEGF cause the demyelinating polyneuropathy characteristic of POEMS?
The neuropathy in POEMS is a length-dependent demyelinating sensorimotor polyneuropathy with uniform slowing, distinct from CIDP. VEGF likely increases endoneural vascular permeability, exposing myelin to serum cytokines and complement, but the exact pathogenic cascade is not established.
What is the optimal VEGF level cutoff for monitoring treatment response and predicting relapse?
VEGF is used as a biomarker for diagnosis and monitoring, but there is no consensus on the threshold that defines adequate treatment response. Plasma VEGF avoids platelet-derived confounding seen with serum VEGF, but standardized cutoffs are lacking.
Recent Updates
Daratumumab emerging as treatment option for relapsed POEMS
Anti-CD38 monoclonal antibody daratumumab, alone or in combination regimens, is being explored for relapsed/refractory POEMS syndrome. Early case series and retrospective data show promising hematologic and VEGF responses, particularly in patients who have failed prior lines of therapy including transplant.
VEGF validated as reliable response biomarker across treatment modalities
Accumulating evidence confirms that plasma VEGF levels track treatment response across all modalities (ASCT, lenalidomide, bortezomib, radiation). Pre-transplant VEGF response predicted superior 5-year PFS (90.9% vs 47.4%). Plasma VEGF (rather than serum) is preferred to avoid platelet-derived confounding.
Improved transplant outcomes in the modern era
Contemporary autologous stem cell transplant series show 10-year overall survival approaching 80%, with transplant-related mortality decreasing to 2-5%. Better patient selection, supportive care, and pre-transplant debulking with bortezomib or lenalidomide have contributed to improved outcomes.
Lenalidomide plus dexamethasone long-term data confirm durable responses
Extended follow-up of lenalidomide-dexamethasone treated patients shows 3-year OS of 90% and 3-year PFS of 75% with neurologic response rates of 95%. Low-dose lenalidomide (10-25 mg) combined with dexamethasone appears well tolerated with no treatment-related deaths reported in the prospective He et al. 2018 study.
Single-cell analysis reframes VEGF pathogenesis: plasma cells produce IL-6, not VEGF
Isshiki et al. (2022) used single-cell RNA-Seq to show POEMS clonal plasma cells do not directly upregulate VEGF mRNA. Instead, they overexpress IL-6, which induces VEGF production in bystander cells. This reframes the pathogenic cascade and suggests IL-6 as an upstream therapeutic target.
Bortezomib-based induction before ASCT improves VEGF response and PFS
Li et al. (2021) reported that bortezomib-based induction therapy (VCD or VRD) prior to autologous stem cell transplant achieved VEGF response in 85% of patients before transplant. Pre-transplant VEGF normalization was associated with superior 5-year PFS compared to transplant without bortezomib induction, establishing bortezomib-based debulking as standard pre-transplant care.
International consensus diagnostic criteria updated with VEGF threshold
Dispenzieri (2019) proposed updated diagnostic criteria incorporating a plasma VEGF threshold of greater than 200 pg/mL as a major criterion, replacing the previous requirement for extravascular volume overload. The updated criteria improve sensitivity for early-stage POEMS while maintaining specificity against other plasma cell dyscrasias.
Thrombotic microangiopathy identified as driver of renal dysfunction in POEMS
Kidney biopsy series from Nakahama et al. (2020) established that thrombotic microangiopathy, rather than glomerulonephritis, is the predominant renal pathology in POEMS syndrome. VEGF-driven endothelial injury causes small vessel thrombosis and glomerular ischemia, explaining why renal function improves with VEGF-lowering treatments.
Japanese nationwide survey establishes largest epidemiological dataset for POEMS
Nozaki et al. (2023) conducted a nationwide survey across Japan identifying 566 POEMS patients, estimating prevalence at approximately 0.3 per 100,000. The study confirmed Japan has the highest reported POEMS incidence globally, with median age at diagnosis of 54 years and male predominance of 1.6:1.
Phase II trial of ixazomib-dexamethasone shows oral-only regimen feasibility
Dispenzieri et al. (2022) reported the first prospective trial of oral proteasome inhibitor ixazomib plus dexamethasone in POEMS, achieving hematologic response in 71% and neurologic improvement in 78% of patients. This all-oral regimen offers a convenient alternative for transplant-ineligible patients unable to attend frequent infusion visits.